Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited launched their Nasodine nasal spray in the US and Singapore, marking a significant expansion of their product availability. Despite initial limited sales in the US due to seasonal factors, expectations are high for growth with the upcoming winter season. The company also secured a new patent in South Africa and raised $800,000 through a share placement to support Nasodine’s launch and working capital needs.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
